Taro Receives FDA Approval For Imiquimod Cream, 5%

Taro Pharmaceutical Industries Ltd. ("Taro," or the "Company," Pink Sheets: TAROF) reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application (ANDA) for Imiquimod Cream, 5% ("imiquimod cream").


Taro's imiquimod cream is a prescription pharmaceutical product used for topical treatment of actinic keratosis and external genital warts and is bioequivalent to Aldara® Cream, 5% of Graceway Pharmaceuticals, LLC.


According to industry sources, imiquimod cream had annual sales of approximately $340 million in the U.S.


Aldara® is a registered trademark of Graceway Pharmaceuticals, LLC.